SEC Form 4 · accession 0001214659-18-000368
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jamie Christensen
Officer — SVP, Chief Science Officer
Period of report
Jan 11, 2018
Accepted (ET)
Jan 11, 2018 · 7:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 11, 2018 | M | 4,000 | $8.50 | A | 6,395 | D | |
| Common Stock | Jan 11, 2018 | M | 10,500 | $17.41 | A | 16,895 | D | |
| Common Stock | Jan 11, 2018 | S | 225 | $22.00 | D | 16,670 | D | |
| Common StockF2,F5 | Jan 11, 2018 | S | 14,500 | $23.0018 | D | 2,877 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $8.50 | Jan 11, 2018 | M | 4,000 | D | — | Jul 16, 2020 | Common Stock | 4,000 | 0 | D |
| Employee Stock Option (Right to Buy)F4 | $17.41 | Jan 11, 2018 | M | 10,500 | D | — | May 20, 2024 | Common Stock | 10,500 | 44,750 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $23 to $23.005. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3Twenty percent (20%) of the shares subject to the stock option vested and became exercisable on the grant date of the option (July 17, 2013), and an additional 20% shall vest and become exercisable each year on the anniversary of the grant date.
- F41/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
- F5Includes 707 shares acquired under the ESPP Purchase on 11/30/17.